Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
复制标题
DOI：
10.1016/j.cgh.2006.03.002
复制
发表时间：
2006-05-01
影响因子：
12.6
通讯作者：
Sandborn, WJ
中科院分区：
文献类型：
--
作者：
Lichtenstein, GR;Feagan, BG;Sandborn, WJ
背景与目的：需要英夫利西单抗和其他治疗克罗恩病（CD）的长期安全性数据。方法：我们前瞻性地评估了患者预先规定的安全性相关结局。结果如下：截至2004年8月，6290例患者入组; 3179例接受英夫利西单抗（5519患者-年），其中87%接受至少2次输注，3111例接受其他治疗（6123患者-年）。平均随访评价时间为1.9年。更多接受英夫利昔单抗治疗的患者患有中度至重度（30.8% vs 10.3%）或重度暴发性（2.5% vs 6%）CD，并且在前一年接受过手术（17.5% vs 13.8%）或内科（14.4% vs 9.1%）住院治疗。与接受其他治疗的患者相比，更多的患者使用泼尼松（27.4% vs 16.1%）、免疫调节剂（49.4% vs 32.2%）或麻醉性镇痛药（9.8% vs 5.4%）（P
Background & Aims: Long-term safety data for infliximab and other therapies in Crohn's disease (C D) are needed. Methods: We prospectively evaluated patients for prespecified safety-related outcomes. Results: As of August 2004, 6290 patients were enrolled; 3179 received infliximab (5519 patient-years), 87% of whom received at least 2 infusions, and 3111 received other therapies (6123 patient-years). The mean length of follow-up evaluation was 1.9 years. More infliximab-treated patients had moderate-to-severe (30.8% vs 10.3%) or severe-fulminant (2.5% vs.6%) CD, and had surgical (17.5% vs 13.8%) or medical (14.4% vs 9.1%) hospitalizations in the previous year. More patients were taking prednisone (27.4% vs 16.1%), immunomodulators (49.4% vs 32.2%), or narcotic analgesics (9.8% vs 5.4%) when compared with those receiving other therapies (P